The Orphan drug Summit was very interesting in many ways.
It looks like the landskape for the Pharma industry is changing and that they are becoming more and more interested in investing in orphan drugs.
Bruno Strigini said that most of the big pharma were going into the orphan drug sector since they are loosing money on the “normal” drugs. The cost of producing and of performing trials is less.
This is good news for the AHC community and all rare diseases.
I met some extremely interesting people that have great insight into new technology and the future of medicine.
Hopefully this summit will prove to be a step towards big achievements for Alternating Hemiplegia of Childhood.
SJ
